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• Atrial Fibrillation is a common post-operative complication that may 
occur in up to 40% of patients following cardiothoracic surgery (CTS)
• Caused by pre-existing degenerative changes to myocardium and 
perioperative conditions that alter electrophysiological parameters
• Per P&T approved protocol, all patients undergoing CTS will be initiated 
prophylactic medications post-operatively unless contraindicated. After 
extubation, patients will be switched to oral equivalents
• Amiodarone 150 mg IV bolus followed by amiodarone infusion 1 
mg/minute x6 hours then decrease rate to 0.5 mg/min x 18 hours
• Metoprolol 5 mg IV every 6 hours, Hold for SBP < 100 or HR < 60 or if 
currently paced via epicardial wires
• Ketorolac 30 mg IV every 6 hours x 48 hours while intubated reduce 
dose to 15 mg IV every 6 hours for CrCl 25-50 mL/min. Do not give 
ketorolac if patient is actively bleeding or CrCl < 25 mL/min
• In April 2018, an interim analysis was done on 50 patients pre protocol 
implementation, and 100 patients post protocol implementation
• This interim analysis helped guide nurses by helping to establish 
current hold parameters for protocol medications
• Compare the incidence of POAF CTS patients prior to and after 
implementation of a protocol that standardizes the prophylactic 
management of Post-Operative Atrial Fibrillation (POAF) in all post-
operative patients
• Study Design: Single center, IRB exempt, retrospective chart review pre 
and post protocol implementation
• Data Collection Period:
• Pre Implementation: June 1st, 2017 to August 31st, 2017
• Interim Evaluation: October 1st, 2017 to February 29th,  2018
• Ad Hoc: March 1st, 2018 to October 21st 2018
• Inclusion criteria
• Age ≥ 18 years
• Received Coronary Artery Bypass Graft and/or valvular surgery during 
pre and post protocol implementation periods listed above
• Exclusion criteria
• Active atrial fibrillation/flutter or either arrhythmia at time of surgery
• Primary Endpoint
• Incidence of POAF in CTS, patients prior to and after protocol 
implementation
• Secondary Endpoint
• Intensive Care Unit (ICU) and hospital Length of Stay (LOS)
• Safety of protocol medications
• P&T approved protocol compliance
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• Incidence of POAF following CTS has reduced from 36% pre protocol to 22% post protocol 
with a relative risk reduction of 39%
• Prescribing of amiodarone and NSAIDs through this protocol has continued to improve post 
protocol implementation
• The number of protocol medications received is indirectly proportional to incidence of POAF 
development
• History of Atrial Fibrillation poses a major risk for POAF development after CTS
• The study contributors have nothing to disclose regarding any financial or nonfinancial 
relationships with the products described, reviewed, or evaluated in this presentation.
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Pre Interim Ad Hoc
No POAF (n=117) POAF (n=33)
History of atrial fibrillation, n (%) 9 (8) 15 (45)
Mitral valvular disease, n (%) 9 (8) 6 (18)
Time on cardiopulmonary bypass (min) 98 139
Hypotension requiring vasopressors, n (%) 51 (44) 21 (64)
Pre Interim Ad Hoc
ICU LOS (days) 3 3.3 3.3
Hospital LOS (days) 8 8.9 8.8
LIMITATIONS
• Small sample size
• Two different investigators at different stages of the data collection
Length of Stay
Pre
(n=50)
Interim
(n=100)
Ad Hoc
(n=50)
Age (years) 63 63 64
Gender - male, n (%) 35 (70) 70 (70) 32 (64)
CABG 32 (64) 60 (60) 36 (72)
x1 3 (6) 11 (11) 6 (12)
x2 13 (26) 21 (21) 21 (44)
x3 15 (30) 21 (21) 13 (26)
x4 1 (2) 7 (7) 1 (2)
Valvular 12 (24) 30 (30) 9 (18)
Aortic 6 (12) 21 (21) 5 (10)
Mitral 6 (12) 10 (10) 4 (8)
Combined 6 (12) 10 (10) 5 (10)
Emergent 24 (48) 49 (49) 29 (58)
Baseline Characteristics
OUTCOMES
Risk Factor Comparison (n=150)
No POAF (n=117) POAF (n=33)
Number of agents received
All three agents received, n (%) 52 (44) 8 (24)
Two agents received, n (%) 44 (38) 9 (27)
One agent received, n (%) 19 (16) 12 (36)
No agent received, n (%) 2 (2) 4 (12)
Protocol Compliance (n=150)
Metoprolol Amiodarone NSAID
Received Therapy 114 127 76
ADR Requiring Dose Reduction or 
Discontinuation 18 31 12
Safety Evaluation (n=150)
Overall post protocol 
incidence of POAF = 22%
